An observational study in Lymphoma and Hemophagocytic Lymphohistiocytoses, sponsored by University of Alabama at Birmingham. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-01-22.
Sponsored by University of Alabama at Birmingham · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,910 studies in Lymphoma with a site in United States — 161 open to participants now, 288 under way, 15 of them phase 3. Lymphoma · United States.
Among the 1,910 studies in Lymphoma with a site in United States, this one is the 17th largest by planned enrollment of the 160 observational ones that give a count, is one of 42 that started in 2023, is one of 160 observational ones, reaches primary completion later than 187 of the 281 other live ones, and was the 1,785th registered.
3,020 studies on the registry are indexed under Lymphoma; 434 are open to participants now.
Browse Lymphoma studies →161 of the 1,910 studies in Lymphoma with a site in United States are open now. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–110 · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,910 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 800 · Phase 2 893 · Phase 3 109 · Phase 4 10
First in 1986; this study’s year is marked. 42 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 168 across 394 observational studies indexed under Lymphoma.
Median enrollment 36 across the 1,595 interventional studies, 120 across the 160 observational. Of the 1,506 that completed or were terminated, 581 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
514 of 1,910 have an industry lead sponsor. The 10 most frequent:
University of Alabama at Birmingham is the lead sponsor of 1,422 studies on the registry; 277 are open to participants now.
Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.
University of Alabama at Birmingham has 8 studies filed under Lymphoma — fewer than ten, so there is no comparison to draw.
89 of the studies in Lymphoma with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04529772Phase 3Acerta Pharma BVA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | 2027-02-22 |
| NCT03823534Phase 3St. Louis UniversityPost-Op Pain Control for Prophylactic Intramedullary Nailing. | 2027-03-31 |
| NCT05006482Phase 3University of RochesterGeriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial | 2027-05-17 |
| NCT06356129Phase 3CelgeneStudy to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma | 2027-08-09 |
| NCT06084936Phase 3Hoffmann-La RocheA Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma | 2027-08-31 |
Add all 89 to your calendar (.ics) → With an account.
Among the 1,910 studies in Lymphoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to describe Hemophagocytic lymphohistiocytosis (HLH) in patients with lymphoma to identify possible therapeutic strategies to improve overall survival of the patients with lymphoma associated hemophagocytic lymphohistiocytosis.
Retrospective, multi-institutional study focused on describing the clinical features, laboratory parameters, treatments, and outcomes among individuals presenting with HLH in the setting of a lymphoma
Patients with diagnosis of Hemophagocytic lymphohistiocytosis (HLH)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A. Meeting 5 of 8 HLH-2004 diagnostic criteria OR B. Are OHI index positive (sCD25>3,900 U/mL and ferritin>1,000 ng/mL)
Exclusion Criteria:
To determine the factors predicting 180 days overall survival of patients with cancer that are HLH-2004/OHI+
The investigators will gather data on different treatments received, time to treatment, and other factors and determine which is associated with survival.
Time frame: The participant's survival would be assessed at 180 days from the malignancy diagnosis
Started May 2023 (actual). Primary completion is estimated for Jan 2028, 56 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Alabama at Birmingham →